MAPT and Cognitive impairment: A previous investigation demonstrated that elevated Aβ42, P-T181-tau, and P-S936-tau, and reduced NRGN and REST levels in plasma NDEV distinguished control subjects from mild to moderate AD patients and from patients with mild cognitive impairment (MCI) who progressed to AD with a high sensitivity [10].